2026年1月19日至23日，来自中国、欧洲中东及非洲、北美、亚太和南美五大区域市场的一线销售、市 场、临床支持、客服、运营及区域管理团队等数百名时代天使员工在无锡齐聚一堂，共同召开2026海外 员工大会。这些员工共同支撑着时代天使在全球60多个国家的业务发展，并将继续陪伴时代天使迈向下 一个增长周期。 区域圆桌论坛 本次会议日程紧凑而丰富，涵盖各区域业务会议、员工表彰、全员大会、区域负责人圆桌讨论等多个环 节，并通过晚宴与团队建设活动，持续加深跨区域、跨职能之间的协作与连接，为全球团队建立更紧密 的沟通基础。 大会现场气氛热烈 大会特别邀请公司多位"元老级员工"与核心管理层成员，系统回顾了时代天使23年的发展历程，让更多 员工理解时代天使一路走来的关键选择与长期坚持，也更深刻体会"客户至上"价值观背后的传承与创 新。时代天使始终坚持以医学为本，以解决真实临床问题为核心目标，并以这种专业、被尊重的方式， 将中国正畸带向世界。 目前，时代天使全球市场(中国以外)主要聚焦发达国家市场，以直销模式为主，团队高度本地化，各区 域团队均在当地招聘，普遍拥有多年正畸行业经验，是真正"懂行业、懂医生、懂本地市场"的团队。同 ...

Group 1 - Morgan Stanley increased its stake in Times Angel (06699) by 649,218 shares at a price of HKD 66.6301 per share, totaling approximately HKD 43.2575 million [1] - After the increase, Morgan Stanley's total shareholding in Times Angel is approximately 22.6352 million shares, representing a holding percentage of 13.25% [1]

智通财经APP获悉，香港联交所最新资料显示，1月14日，摩根大通增持时代天使(06699)64.9218万股， 每股作价66.6301港元，总金额约为4325.75万港元。增持后最新持股数目约为2263.52万股，最新持股比 例为13.25%。 ...

Group 1 - The Hang Seng Technology Index increased by 1.93% and the Hang Seng Index rose by 1.32% [1] - Notable stock performances include: Zhaoyi Innovation up by 45.06%, Dali Group Holdings up by 13.35%, and Rongchang Bio up by 8.84% [1] - Declining stocks include: Times Angel down by 4.96%, Master Kong Holdings down by 4.18%, and CIMC Enric down by 3.72% [1]

Core Viewpoint - Angelalign (06699) has seen a stock price increase of over 5%, currently trading at 68.7 HKD, with a transaction volume of 23.6952 million HKD, following the announcement of receiving the MDR-CE certification from TÜV Süd [1] Group 1: Certification and Market Impact - Angelalign recently held a certification ceremony in Shanghai, where TÜV Süd officially awarded the MDR-CE certificate, indicating compliance with EU medical device regulations [1] - The MDR-CE certification signifies that Angelalign's products meet the EU's stringent legal requirements for safety, effectiveness, and lifecycle compliance, enhancing international recognition and market credibility [1] - CEO Hu Jiezhang stated that after over two years of international development, Angelalign's overseas business has grown rapidly, with international cases accounting for over 50% of total cases in the first half of this year, covering over 60 countries and regions [1] Group 2: Strategic Importance - The receipt of the CE certification marks a significant milestone in Angelalign's globalization process, further solidifying the company's competitive foundation in the international invisible orthodontics market [1]

获得MDR-CE证书代表时代天使产品完全满足欧盟对医疗器械安全性、有效性及全生命周期合规性的强 制性法律要求，具有极高的国际认可度与市场公信力。时代天使CEO胡杰章在授证仪式上表示，经过两 年多的国际化发展，时代天使海外业务增长迅速，今年上半年的国际病例数占总案例数比例已超过 50%，业务覆盖60多个国家和地区。此次获得CE认证，是时代天使全球化进程中的重要里程碑，也将 进一步夯实公司在国际隐形矫治市场中的竞争基础。 消息面上，据时代天使官网消息，近日，时代天使在上海举办MDR-CE证书授证仪式。T V南德意志集 团(以下简称"T V南德")在授权仪式上为时代天使正式颁发CE实体证书。此次获得国际权威欧盟公告机 构(Notified Body)的认可，标志着时代天使隐形矫治相关产品在安全性、有效性及合规性方面全面符合 欧盟医疗器械法规要求，也意味着时代天使在高标准海外市场准入上迈出重要一步。 时代天使(06699)涨超5%，截至发稿，涨4.57%，报68.7港元，成交额2369.52万港元。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 時代天使科技有限公司 呈交日期: 2026年1月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06699 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 | USD | | 0.0001 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 500,000,000 | USD | | 0.0001 | USD | | 50,000 | 本月底法定/註冊股本總額： ...

Investment Rating - The report suggests a positive investment outlook for the medical device sector, particularly in brain-computer interface devices, which are expected to see accelerated commercialization due to supportive policies [1][3]. Core Insights - Recent policies have significantly increased support for innovation in medical devices, with the National Medical Products Administration actively promoting faster market entry for brain-computer interface devices, indicating a diverse application landscape and substantial future potential [1][3]. - The pharmaceutical sector is witnessing positive developments, such as GSK's approval of mepolizumab for a new indication in COPD patients, marking it as the first monthly administered biologic in China, which is expected to reduce the annual incidence of severe exacerbations significantly [1][32]. - The report highlights the approval of Wegovy® tablets in the U.S. for weight management, emphasizing its potential impact on the market as the first oral GLP-1 receptor agonist for this purpose [37][40]. Summary by Sections Pharmaceutical Sector - Mepolizumab has been approved for COPD treatment in China, with a monthly dosing schedule, targeting a significant patient population [1][32]. - The A/H share innovation drug sector maintains high activity levels, with new drug approvals and cross-border transactions remaining robust [16][28]. Biologics - Wegovy® tablets have been approved in the U.S. for weight management, showing similar weight loss efficacy to its injectable counterpart, with a significant portion of participants achieving substantial weight loss [37][40]. CXO and Pharmaceutical Supply Chain - The CXO sector continues to show upward momentum, supported by a stable order backlog, with November financing levels slightly above the annual average [44][46]. Medical Devices - The centralized procurement process for high-value medical consumables is progressing steadily, with high selection rates in multiple rounds of bidding, indicating a favorable environment for leading domestic companies [2][52]. Retail Pharmacy - The industry is undergoing a consolidation phase, with leading companies expected to benefit from increased market share through mergers and acquisitions [2][3]. Medical Services and Consumer Healthcare - Aier Eye Hospital's acquisition of 39 institutions for 960 million yuan strengthens its market position, with the acquired entities showing signs of financial recovery [2][3].

12月26日，时代天使(06699.HK)官微发布消息称，近日，时代天使在上海举办MDR-CE证书授证仪式。 T V南德意志集团(T V南德)代表团为时代天使正式颁发CE实体证书。此次获得国际权威欧盟公告机构 (Notified Body)的认可，标志着时代天使隐形矫治相关产品在安全性、有效性及合规性方面全面符合欧 盟医疗器械法规要求，也意味着时代天使在高标准海外市场准入上迈出重要一步。 他表示，自启动全球化战略以来，时代天使选择优先进入欧美等发达市场，这意味着企业必须在法规理 解、数据安全、产品质量、认证流程等方面全面对标西方最高标准，并以当地医生的使用习惯和认知逻 辑来提供产品与服务。为此，时代天使在国际市场坚持高度本地化策略，围绕牙医这一高专业度人群， 持续优化产品与服务体系。 经过两年多的国际化发展，时代天使海外业务增长迅速，今年上半年的国际病例数占总案例数比例已超 过50%，业务覆盖60多个国家和地区。此次获得CE认证，是时代天使全球化进程中的重要里程碑，也 将进一步夯实公司在国际隐形矫治市场中的竞争基础。 据介绍，T V南德是欧盟官方授权的公告机构，在医疗器械认证领域具有全球公认的专业权威性。本次 ...

T V南德是欧盟官方授权的公告机构，在医疗器械认证领域具有全球公认的专业权威性。本次时代天使 所获的MDR-CE证书，是依据欧盟《医疗器械法规》(Medical Device Regulation，MDR)颁发的准入凭 证，MDR也是全球最严格的医疗器械监管体系之一，获得这项证书需经过公告机构对产品技术、临床 评价、质量管理体系及上市后监督等多个维度的系统性、多轮次严格审核，流程严谨、复杂，标准极 高。因此，获得MDR-CE证书代表时代天使产品完全满足欧盟对医疗器械安全性、有效性及全生命周期 合规性的强制性法律要求，具有极高的国际认可度与市场公信力。 时代天使CEO胡杰章表示，作为全球隐形矫治品牌，时代天使获得CE认证源于公司在产品研发、质量 体系与合规能力上的长期积累，也得益于T V南德在专业层面的严格要求。自启动全球化战略以来，时 代天使选择优先进入欧美等发达市场，这意味着企业必须在法规理解、数据安全、产品质量、认证流程 等方面全面对标西方最高标准，并以当地医生的使用习惯和认知逻辑来提供产品与服务。 本报讯(记者李春莲)近日，时代天使生物科技有限公司(以下简称"时代天使")在上海举办MDR-CE证书 授证 ...